Biolegend, 423103, Zombie Yellow™ Fixable Viability Kit
100tests
Catalog Number: 423103
Send an RFQ.
Category
Pack Size1 vial
Loading…
| Preparation | Zombie Yellow™ Fixable Viability Kit is composed of lyophilized Zombie Yellow™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Yellow™ dye until fully dissolved. 100 tests = 1 vial of Zombie Yellow™ + DMSO, 500 tests = 5 vials of Zombie Yellow™ + DMSO. |
|---|---|
| Storage & Handling | Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Yellow™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type. |
| Excitation Laser | Violet Laser (405 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Zombie Yellow™ dye is excited by the violet laser and has a fluorescence emission maximum of 572 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Yellow™ dye has similar emission to Brilliant Violet 570™. Standard Cell Staining Protocol: Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Yellow™ dye and mix until fully dissolved Wash cells with PBS buffer (no Tris buffer and protein free). Dilute Zombie Yellow™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Yellow™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA. Continue performing antibody staining procedure as desired. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation. No-wash Sequential Staining Protocol: Wash cells with PBS buffer (no Tris buffer and protein free). For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Yellow™ dye and mix until fully dissolved Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie Yellow™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µl total staining volume, use 80 µL of Zombie Yellow™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Yellow™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells. Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Yellow™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Yellow™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Yellow™. |
| Application References(PubMed link indicates BioLegend citation) | Talabot-Ayer D, et al. 2015. J Immunol. 194:750. PubMed Keppel MP, et al. 2015. J Immunol. 194:1954. PubMed Shade KT, et al. 2015. J Exp Med. 212:457. PubMed Souza-Fonesca-Guimaraes F, et al. 2015. PNAS. 112:2376. PubMed Weiser JN, et al. 2015. J Infect Dis. PubMed |
|---|
| Product Citations | Souza-Fonseca-Guimaraes F, et al. 2016. Cell Death Dis. 7:e2302. PubMed Wang X, et al. 2019. Cell Res. 29:787. PubMed Rose JR, et al. 2023. Commun Biol. 6:363. PubMed Makaryan V, et al. 2022. J Cell Immunol. 4:19. PubMed Larue MM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2119168119. PubMed Telzrow CL, et al. 2022. Infect Immun. 90:e0058021. PubMed Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed Kania AK, et al. 2022. J Immunol. 208:1873. PubMed Reglero-Real N, et al. 2021. Immunity. :. PubMed Zhou T, et al. 2020. Nature. 583:609. PubMed Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed Allegrezza M, et al. 2016. Cancer Res . 76: 6253 - 6265. PubMed Weiser J, et al. 2015. J Infect Dis. 212: 1677 - 1682. PubMed Zhao B, et al. 2020. Nat Commun. 11:908. PubMed Murayama G,et al. 2017. Arthritis Res Ther.. 10.1186/s13075-017-1441-7. PubMed Park SY, et al. 2022. NPJ Vaccines. 7:123. PubMed Liang Q, et al. 2022. iScience. 25:104043. PubMed Souza-Fonseca-Guimaraes F, et al. 2015. Proc Natl Acad Sci U S A. 112:2376. PubMed Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed Peterson L, et al. 2016. J Immunol. 197: 4110 - 4117. PubMed Philip N, et al. 2016. PLoS Pathog. 12:e1005910. PubMed Renshaw H, et al. 2016. Infect Immun . 84: 1556 - 1564. PubMed Shade K, et al. 2015. J Exp Med. 212:457. PubMed El–Achkar GA, et al. 2019. PLoS One. 14:e0216405. PubMed Alturki NA, et al. 2018. Cell Death Dis. 9:592. PubMed Mathivet T, et al. 2017. EMBO Mol Med.. 10.15252/emmm.201607445. PubMed Booty MG, et al. 2022. J Immunol. 208:929. PubMed Stephenson E, et al. 2021. Nat Med. 27:904. PubMed Rodriguez-Garcia M, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.72. PubMed Fisher J, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.03.002. PubMed Hoppstädter J, et al. 2019. Front Immunol. 10:1634. PubMed Haines RR, et al. 2018. J Immunol. 201:2799. PubMed Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed Perales-Puchalt A, et al. 2017. Clin Cancer Res. 23(2):441-453. PubMed Fallet B, et al. 2020. Cell Rep. 30:1013. PubMed Hole CR, et al. 2019. Nat Commun. 10:2955. PubMed Talabot-Ayer D, et al. 2015. J Immunol. 194:750. PubMed Keppel M, et al. 2015. J Immunol. 194:1954. PubMed Ludwik KA, et al. 2021. STAR Protocols. 2(1):100270. PubMed Lima LG, et al. 2021. Nat Commun. 12:3543. PubMed Wang JC, et al. 2022. Elife. 11:. PubMed Zhang S, et al. 2021. Cancer Discov. 0.709722222. PubMed Putz EJ, et al. 2019. J Dairy Sci. 102:9268. PubMed Chung NH, et al. 2022. Vaccine. 40:574. PubMed Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed Zanvit P, et al. 2015. Nat Commun. 6: 8424. PubMed Lombardi M, et al. 2016. J Leukoc Biol. 99: 711 - 721. PubMed Palomo J, et al. 2016. J Immunol. 197: 2239 - 2249. PubMed Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed Grubišic V, et al. 2022. Mucosal Immunol. 15:964. PubMed Islam MR, et al. 2022. Nanotheranostics. 6:451. PubMed Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed Keller A, et al. 2017. Nat Immunol. 18:402-411. PubMed Tanaka Y, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.46. PubMed Huang N, et al. 2020. Genome Biol. 1.03125. PubMed Lim J, et al. 2022. J Exp Med. 219:. PubMed Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed Davidson TB, et al. 2019. Clin Cancer Res. 25:1913. PubMed Wu S, et al. 2021. Nat Cancer. 2:189. PubMed Mittal D, et al. 2016. Cancer Res . 76: 264 - 274. PubMed Shorter S, et al. 2016. PLoS One. 11: 0149582. PubMed Spiliopoulou P, et al. 2022. Mol Cancer Ther. . PubMed Behrens GMN, et al. 2022. Nat Commun. 13:4872. PubMed Njock MS, et al. 2022. J Extracell Vesicles. 11:e12228. PubMed Herati RS, et al. 2022. Nat Immunol. 23:1183. PubMed Binette P, et al. 2022. Front Immunol. 13:894536. PubMed Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed Trial J, et al. 2020. Geroscience. . PubMed Singh KS, et al. 2021. Nature. 589:597. PubMed Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed DeFalco T, et al. 2016. Cell Rep. 12: 1107-1119. PubMed Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed Tao Z, et al. 2022. Cells. 11:. PubMed Burel J, et al. 2016. PLoS Pathog. 12: 1005839. PubMed Haines RR, et al. 2019. J Immunol. 203:1867. PubMed Wang X, et al. 2021. Sci Transl Med. 13:. PubMed Waldman MM, et al. 2022. Front Immunol. 13:856977. PubMed Teshima T, et al. 2022. Oncol Lett. 24:265. PubMed Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed Zheng W, et al. 2019. Cell Rep. 29:1747. PubMed Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed |
|---|
| Biology Area | Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience |
|---|
| Gene ID | NA |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Fixable Dye, Fixable Viability Dye, Dead, Apoptosis |
|---|
